ASX Share rice
Sun 16 May 2021 - 07:10:am (Sydney)

GSS Share Price

GENETIC SIGNATURES LIMITEDGSSPharmaceuticals, Biotechnology & Life Sciences

GSS Company Information

Name:

Genetic Signatures Limited

Sector:

Healthcare

Industry:

Diagnostics & Research

GIC Industry:

Life Sciences Tools & Services

GIC Sub Industry:

Life Sciences Tools & Services

Address:

7 Eliza Street Sydney NSW Australia 2042

Phone:

61 2 9870 7580

MD, CEO & Exec. Director:

Dr. John R. Melki

CFO & Company Sec.:

Mr. Peter Manley

Exec. Director of US Operations & Exec. Director:

Mr. Michael Anton Aicher M.B.A., BSc, MBA

Founder & Chairman Emeritus:

Mr. Christopher M. Abbott

Chief Scientific Officer:

Dr. Douglas S. Millar BSc, Ph.D.

Director of Global Sales & Marketing:

Mr. Jackson Jones

US Market Consultant:

Mr. Patrick Noland BSc, MBA

Company Overview:

Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in North America and Australia. The company designs and manufactures a suite of real-time polymerase chain reaction based products for detection of infectious diseases under EasyScreen brand name. It also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. Genetic Signatures Limited was founded in 2001 and is headquartered in Sydney, Australia.

GSS Share Price Information

Shares Issued:

142.91M

Market Capitalisation:

$177.20M

Revenue (TTM):

$29.13M

Revenue Per Share (TTM):

$0.20

Earnings per Share:

$0.033

Profit Margin:

0.1633

Operating Margin (TTM):

$0.16

Return On Assets (TTM):

$0.06

Return On Equity (TTM):

$0.10

Quarterly Revenue Growth (YOY):

4.11

Gross Profit(TTM):

$7.83M

Diluted Earnings Per Share (TTM):

$0.033

GSS CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-2,350,000

Change To Liabilities:

$1.32M

Total Cashflow From Investing Activities:

$-2,350,000

Net Borrowings:

$-299,000

Net Income:

$-2,086,000

Total Cash From Operating Activities:

$-9,494,000

Depreciation:

$883K

Change To Inventory:

$-5,899,000

Change To Account Receivables:

$-4,360,000

Sale Purchase Of Stock:

$38.88M

Capital Expenditures:

$2.35M

GSS Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-2,086,000

Net Income:

$-2,086,000

Gross Profit:

$8.01M

Operating Income:

$-2,005,000

Other Operating Expenses:

$1.60M

Interest Expense:

$33K

Total Revenue:

$14.09M

Cost Of Revenue:

$6.07M

GSS Balance Sheet

Balance Sheet Date:

2020-06-30

Total Liabilities:

$3.79M

Total Stockholder Equity:

$45.93M

Other Current Liabilities:

$589K

Total Assets:

$49.72M

Common Stock:

$84.01M

Other Current Assets:

$2.55M

Retained Earnings:

$-39,914,000

Other Liabilities:

$20K

Cash:

$31.18M

Total Current Liabilities:

$3.34M

Property - Plant & Equipment:

$3.51M

Net Tangible Assets:

$45.93M

Total Current Assets:

$46.21M

Net Receivables:

$7.78M

Short-Term Investments:

$3.51M

Inventory:

$7.25M

Accounts Payable:

$1.78M

Short-Term Investments:

$3.51

Non Current Liabilities Total:

$448K

GSS Share Price History

GSS News

06 Apr, 2021
It is hard to get excited after looking at Genetic Signatures' (ASX:GSS) recent performance, when its stock has...
05 Feb, 2021
For us, stock picking is in large part the hunt for the truly magnificent stocks. Mistakes are inevitable, but a single...
31 Dec, 2020
With the business potentially at an important milestone, we thought we'd take a closer look at Genetic Signatures...
25 Nov, 2020
A look at the shareholders of Genetic Signatures Limited (ASX:GSS) can tell us which group is most powerful. Generally...
20 Oct, 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
15 Sep, 2020
This article will reflect on the compensation paid to John Melki who has served as CEO of Genetic Signatures Limited...
31 Jul, 2020
Genetic Signatures Limited (ASX:GSS) shareholders will have a reason to smile today, with the covering analyst making...